Valuation: Immuneering Corporation

Market Cap 327M 283M 265M 241M 454M 31.3B 460M 3.11B 1.22B 15.68B 1.23B 1.2B 52.16B P/E 2026 *
-4.45x
P/E 2027 * -3.92x
Enterprise Value 327M 283M 265M 241M 454M 31.3B 460M 3.11B 1.22B 15.68B 1.23B 1.2B 52.16B EV / Sales 2026 *
-
EV / Sales 2027 * 19.2x
Free-Float
86.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immuneering Corporation

1 day+2.17%
1 week+13.91%
Current month+24.94%
1 month+11.21%
3 months+5.95%
6 months+0.78%
Current year-21.58%
1 week 4.55
Extreme 4.55
5.26
1 month 4.03
Extreme 4.03
5.26
Current year 3.86
Extreme 3.86
8.48
1 year 3.25
Extreme 3.25
10.08
3 years 1
Extreme 1
10.25
5 years 1
Extreme 1
33.25
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 31/01/2008
Director of Finance/CFO 61 15/07/2026
Chief Tech/Sci/R&D Officer - 31/07/2023
Director TitleAgeSince
Chairman 81 31/12/2007
Director/Board Member 44 31/01/2008
Director/Board Member 72 26/04/2021
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Other

Chief Financial Officer

225,000 0.3478%
16/07/26 Free

Chief Financial Officer

650,000 1.0047%
03/02/26 Free

Chief Technology Officer

140,000 0.2168%
Change 5-day change 1-year change 3-year change Capi.($)
+2.08%+13.91%+47.43%-41.43% 327M
+4.80%+7.80%+70.64%+114.21% 70.07B
+17.12%+11.50%+49.15%+87.30% 52.87B
+2.70%-5.78%-0.24%+477.88% 27.02B
+2.26%+0.65%+49.19%+10.30% 23.61B
-1.48%-1.17%-18.51%-18.99% 23.38B
-6.00%+13.71%+244.39%+443.26% 19.43B
+3.80%+5.62%+39.57%-15.26% 18.75B
+0.38%-3.15%+20.39%+589.77% 15.85B
+2.13%-1.12%+38.68%+149.36% 12.7B
Average +2.78%-0.65%+54.07%+179.64% 26.4B
Weighted average by Cap. +5.00%-1.13%+55.26%+170.03%

Financials

2026 *2027 *
Net sales - 17.06M 14.73M 13.82M 12.59M 23.67M 1.63B 23.99M 162M 63.48M 817M 64.06M 62.67M 2.72B
Net income -76.79M -66.29M -62.19M -56.65M -107M -7.34B -108M -729M -286M -3.68B -288M -282M -12.24B -86.46M -74.65M -70.03M -63.78M -120M -8.27B -122M -821M -322M -4.14B -325M -318M -13.78B
Net Debt - -
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
57
Date Price Change Volume
17/08/26 US$5.155 +1.88% 110,907
14/08/26 US$5.060 -2.69% 524,219
13/08/26 US$5.200 +2.56% 1,083,858
12/08/26 US$5.070 +5.63% 902,994
11/08/26 US$4.800 +5.96% 1,065,403
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.060USD
Average target price
18.25USD
Spread / Average Target
+260.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMRX Stock